Development, Safety, and Efficacy of Janus Kinase Inhibitors in Rheumatoid Arthritis

Article Figures & Data

Figures

  • Figure 1.

    Tofacitinib: Phase 3 Studies of 1 to 2 Year Duration—ORAL Sync, Standard, and Scan

    DMARD=disease-modifying antirheumatic drug; IR=nonresponder; MTX=methotrexate.Reproduced with permission from IB McInnes, PhD.